SAN DIEGO, Feb. 24, 2014 /PRNewswire/ -- Ambrx Inc.
today announced that Sheila
Gujrathi, M.D., has joined its board of directors. Dr.
Gujrathi is currently the chief medical officer at Receptos
(Nasdaq: RCPT) where she is responsible for the clinical
development of therapeutic candidates for the treatment of immune
and metabolic diseases.
"Sheila is an industry veteran with significant experience in
immunologic and oncologic drug development," said Lawson Macartney, Ph.D., chief executive officer
of Ambrx. "Her leadership in directing and evaluating drug
development programs will be invaluable as we continue to advance
our own and partnered drug candidates of best-in-class
biotherapeutics and antibody-drug conjugates."
Prior to joining Receptos in 2011, Dr. Gujrathi was vice
president of the global clinical research group in immunology at
Bristol‑Myers Squibb (BMS) where she was responsible for the
late-stage clinical development of Orencia®, Nulojix® and other
compounds being developed for rheumatoid arthritis, solid organ
transplant, systemic lupus erythematosus, juvenile idiopathic
arthritis and inflammatory bowel disease. Dr. Gujrathi was at
Genentech from 2002 to 2008 where she held roles of increasing
responsibility in the immunology, tissue growth and repair clinical
development group and served as the Avastin franchise team leader.
Dr. Gujrathi has also been a management consultant in McKinsey
& Company's healthcare practice.
Dr. Gujrathi holds a bachelor of science in biomedical
engineering and a doctor of medicine from Northwestern University. She completed her internal
medicine internship and residency at Brigham and Women's Hospital,
Harvard Medical School, and additional
fellowship training in Allergy/Immunology at UCSF and Stanford.
About Ambrx
Ambrx Inc. is a clinical stage biopharmaceutical company using an
expanded genetic code to create best-in-class biotherapeutics,
including antibody-drug conjugates (ADCs), bispecific antibodies
and proteins with improved pharmacologic properties. The company is
developing ARX201, a long-acting growth hormone that has
successfully completed Phase 2b clinical trials in growth hormone
deficiency. In addition to its most recent ADC collaborations with
Merck, Astellas and Bristol-Myers Squibb, Ambrx has collaborations
to discover and develop products incorporating Ambrx technology
with Bristol-Myers Squibb, Eli Lilly and several undisclosed
companies. Ambrx is advancing a robust portfolio of product
candidates that are optimized for efficacy, safety and ease of use
in multiple therapeutic areas.
For additional information, visit www.ambrx.com
Media Contact:
David Schull
(212) 845-4271
david.schull@russopartnersllc.com
SOURCE Ambrx Inc.